参考文献
[1] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. ST段抬高型心肌梗死患者急诊PCI微循环保护策略中国专家共识[J]. 中华心血管病杂志, 2022, 50(3):221‑230. DOI: 10.3760/cma.j.cn112148‑20211112‑00987.
[2] Galli M, Niccoli G, De Maria G, et al. Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction[J]. Nat Rev Cardiol, 2024, 21(5):283‑298. DOI: 10.1038/s41569‑023‑00953‑4.
[3] Huang D, Qian J, Liu Z, et al. Effects of intracoronary pro‑urokinase or tirofiban on coronary flow during primary percutaneous coronary intervention for acute myocardial infarction: a multi‑center, placebo‑controlled, single‑blind, randomized clinical trial[J]. Front Cardiovasc Med, 2021,8:710994. DOI: 10.3389/fcvm.2021.710994.
[4] Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44(38):3720‑3826. DOI: 10.1093/eurheartj/ehad191.
[5] Xiao Y, Fu X, Wang Y, et al. Effects of different strategies on high thrombus burden in patients with ST‑segment elevation myocardial infarction undergoing primary percutaneous coronary catheterization[J]. Coron Artery Dis, 2019, 30(8):555‑563. DOI: 10.1097/MCA.0000000000000743.
[6] Davis DO MG, Blankenship JC. Improving STEMI reperfusion with intracoronary thrombolysis: a way to "go with the flow"[J]. Cardiovasc Drugs Ther, 2024, 38(2):209‑210. DOI: 10.1007/s10557‑023‑07471‑y.
[7] Ng S, Friede K, Stouffer GA. The case continues to build: more data that intracoronary thrombolysis is safe and effective in STEMI[J]. Cardiovasc Drugs Ther, 2024, 38(2):207‑208. DOI: 10.1007/s10557‑024‑07559‑z.
[8] Hillani A, Potter BJ. Intracoronary thrombus and no‑reflow: one size to fit all?[J]. Can J Cardiol, 2021, 37(2):202‑205. DOI: 10.1016/j.cjca.2020.08.015.
[9] Rao SV, O′Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2025, 85(22):2135‑2237. DOI: 10.1016/j.jacc.2024.11.009.
[10] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志,2019,47(10):766‑783.DOI:10.3760/cma.j.issn.0253‑3758.2019.10.003.
[11] 中华医学会心血管病学分会. 冠状动脉微血管疾病诊断和治疗中国专家共识(2023版)[J]. 中华心血管病杂志, 2024, 52(5):460‑492. DOI: 10.3760/cma.j.cn112148‑20231222‑00521.
[12] 中国医师协会心血管内科医师分会冠状动脉血栓抽吸共识专家组. 冠状动脉血栓抽吸临床应用专家共识[J]. 中华医学杂志, 2017, 97(21):1624‑1632. DOI: 10.3760/cma.j.issn.0376‑2491.2017.21.007.
[13] 国家卫生计生委合理用药专家委员会, 中国药师协会. 急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2019, 11(1):40‑65. DOI: 10.12037/YXQY.2019.01-07.
[14] 替罗非班治疗冠状动脉粥样硬化性心脏病专家共识组. 替罗非班在冠状动脉粥样硬化性心脏病治疗的中国专家共识[J]. 中华内科杂志, 2013, 52(5):434‑439. DOI: 10.3760/cma.j.issn.0578‑1426.2013.05.020.
[15] 血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在冠状动脉粥样硬化性治疗的中国专家共识(2016)专家组. 血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在冠状动脉粥样硬化性心脏病治疗的中国专家共识(2016)[J]. 心肺血管病杂志, 2016, 35(12):923‑932. DOI: 10.3969/j.issn.1007‑5062.2016.12.001.
[16] 中国医师协会心血管内科医师分会, 中国医师协会心血管内科医师分会血栓防治专业委员会, 中华医学会消化内镜学分会, 等. 急性冠状动脉综合征抗栓治疗合并出血防治多学科专家共识[J]. 中华内科杂志, 2016, (10): 813‑824. DOI: 10.3760/cma.j.issn.0578‑1426.2016.10.021.
[17] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组,中国脑出血诊治指南(2019).中华神经科杂志, 2019, 52(12): 994‑1005. DOI: 10.3760/cma.j.issn.1006‑7876.2019.12.003
[18] 中华心血管病杂志(网络版)编辑委员会. 口服抗栓药物相关消化道损伤防治专家共识 [J/OL]. 中华心血管病杂志(网络版),2021,4:e1000081.(2021‑08‑09)[2025‑03‑30]. http://www.cvjc.org.cn/index.php/Column/columncon/article_id/249. DOI:10.3760/cma.j.cn116031.2021.1000081.
[19] Geng W, Zhang Q, Liu J, et al. A randomized study of prourokinase during primary percutaneous coronary intervention in acute ST‑segment elevation myocardial infarction[J]. J Interv Cardiol, 2018, 31(2):136‑143. DOI: 10.1111/joic.12461.
[20] Fu Y, Gu XS, Hao GZ, et al. Comparison of myocardial microcirculatory perfusion after catheter‑administered intracoronary thrombolysis with anisodamine versus standard thrombus aspiration in patients with ST‑elevation myocardial infarction[J]. Catheter Cardiovasc Interv, 2019, 93(S1):839‑845. DOI: 10.1002/ccd.28112.
[21] McCartney PJ, Eteiba H, Maznyczka AM, et al. Effect of low‑dose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction: a randomized clinical trial[J]. JAMA, 2019, 321(1):56‑68. DOI: 10.1001/jama.2018.19802.
[22] Gibson CM, Kumar V, Gopalakrishnan L, et al. Feasibility and safety of low‑dose intra‑coronary tenecteplase during primary percutaneous coronary intervention for ST‑elevation myocardial infarction (ICE T‑TIMI 49)[J]. Am J Cardiol, 2020, 125(4):485‑490. DOI: 10.1016/j.amjcard.2019.11.018.
[23] Wang X, Liu H, Wu H, et al. Safety and efficacy of intracoronary prourokinase administration in patients with high thrombus burden[J]. Coron Artery Dis, 2020, 31(6):493‑499. DOI: 10.1097/MCA.0000000000000853.
[24] Wu Y, Fu X, Feng Q, et al. Efficacy and safety of intracoronary prourokinase during percutaneous coronary intervention in treating ST‑segment elevation myocardial infarction patients: a randomized, controlled study[J]. BMC Cardiovasc Disord, 2020, 20(1):308. DOI: 10.1186/s12872‑020‑01584‑0.
[25] Jiang W, Xiong X, Du X, et al. Safety and efficacy study of prourokinase injection during primary percutaneous coronary intervention in acute ST‑segment elevation myocardial infarction[J]. Coron Artery Dis, 2021, 32(1):25‑30. DOI: 10.1097/MCA.0000000000000898.
[26] Cao M, Wang Z, Meng X, et al. Effects of intracoronary low‑dose prourokinase administration on ST‑segment elevation in patients with myocardial infarction and a high thrombus burden: a randomized controlled trial[J]. J Int Med Res, 2022, 50(12):3000605221139723. DOI: 10.1177/03000605221139723.
[27] Che S, Guo X, Lei Z, et al. Combined intracoronary prourokinase thrombolysis on myocardial perfusion and vascular endothelial function in STEMI[J]. Clin Lab, 2024, 70(7). DOI: 10.7754/Clin.Lab.2024.231137.
[28] Rehan R, Virk S, Wong C, et al. Intracoronary thrombolysis in ST‑elevation myocardial infarction: a systematic review and meta‑analysis[J]. Heart, 2024, 110(15):988‑996. DOI: 10.1136/heartjnl‑2024‑324078.
[29] Alyamani M, Campbell S, Navarese E, et al. Safety and efficacy of intracoronary thrombolysis as adjunctive therapy to primary PCI in STEMI: A systematic review and meta‑analysis[J]. Can J Cardiol,2021,37(2):339‑346. DOI:10.1016/j.cjca.2020.03.034.
[30] Sahami N, Akl E, Sanjanwala R, et al. Safety and efficacy of low‑dose intracoronary thrombolysis during primary percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta‑analysis of randomized trials[J]. Curr Probl Cardiol,2024,49(8):102616. DOI:10.1016/j.cpcardiol.2024.102616.
[31] Alexiou S, Patoulias D, Theodoropoulos K C, et al. Intracoronary thrombolysis in st‑segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: an updated meta‑analysis of randomized controlled trials[J]. Cardiovasc Drugs Ther,2024,38(2):335‑346. DOI:10.1007/s10557‑022‑07402‑3.
[32] Sezer M, Cimen A, Aslanger E, et al. Effect of intracoronary streptokinase administered immediately after primary percutaneous coronary intervention on long‑term left ventricular infarct size, volumes, and function[J]. J Am Coll Cardiol, 2009,54(12):1065‑1071. DOI:10.1016/j.jacc.2009.04.083.
[33] Sezer M, Oflaz H, Gören T, et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med, 2007, 356(18):1823‑1834. DOI: 10.1056/NEJMoa054374.
[34] Gibson C M, de Lemos J A, Murphy S A, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy[J]. Circulation,2001,103(21):2550‑2554. DOI:10.1161/01.cir.103.21.2550.
[35] de Waha S, Patel M R, Granger C B, et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST‑segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials[J]. Eur Heart J,2017,38(47):3502‑3510. DOI:10.1093/eurheartj/ehx414.
[36] Yu S, Jia H, Ding S, et al. Efficacy and safety of intracoronary pro‑urokinase combined with low‑pressure balloon pre‑dilatation during percutaneous coronary intervention in patients with anterior ST‑segment elevation myocardial infarction[J]. J Cardiothorac Surg, 2024, 19(1):180. DOI: 10.1186/s13019‑024‑02699‑7.
[37] Kulick N, Folk D, Friede KA, et al. Association of coronary flow with response to intracoronary tenecteplase in patients with st elevation myocardial infarction with thrombotic complications during primary percutaneous coronary intervention[J]. Am J Cardiol, 2023,206:1‑3. DOI: 10.1016/j.amjcard.2023.08.091.
[38] Chen Y, Liu Y, Li X, et al. Intracoronary microcatheter indwelling for continuous pumping of low‑dose thrombolytic drugs: A new approach to reperfusion in acute myocardial infarction[J]. Medicine (Baltimore), 2024, 103(14):e37692. DOI: 10.1097/MD.0000000000037692.
[39] Chen T, Wang Q, Liu G, et al. Safety and efficacy of intracoronary thrombolytic therapy via a new infusion catheter in patients with ST‑segment elevation myocardial infarction with large thrombus burden: a pilot study[J]. Coron Artery Dis, 2021, 32(3):205‑210. DOI: 10.1097/MCA.0000000000000915.
[40] Zhang Z, Sheng Z, Che W, et al. Design and rationale of the ATTRACTIVE trial: a randomised trial of intrAThrombus Thrombolysis versus aspiRAtion thrombeCTomy during prImary percutaneous coronary interVEntion in ST‑segment elevation myocardial infarction patients with high thrombus burden[J]. BMJ Open,2023,13(11):e076476. DOI:10.1136/bmjopen‑2023‑076476.
[41] 王红娟. 冠脉内应用重组人尿激酶原或瑞替普酶溶栓治疗对高血栓负荷STEMI患者心肌血流灌注及预后的影响研究[D]. 石家庄:河北医科大学,2023.
[42] Huang D, Ma Y, Wu H, et al. Impact of intracoronary reteplase during primary percutaneous coronary intervention on infarct size in large anterior myocardial infarction: rationale and design of the RECOVER II trial[J]. Cardiovasc Diagn Ther,2022,12(3):352‑359. DOI:10.21037/cdt‑21‑756.
[43] 乔智力, 徐彪, 杨骄霞, 等. 冠状动脉内注射瑞替普酶对急性心肌梗死患者PCI术后的影响[J]. 中国老年学杂志, 2017, 37(5):1111‑1113. DOI: 10.3969/j.issn.1005‑9202.2017.05.031.
[44] McCartney PJ, Maznyczka AM, Eteiba H, et al. Low‑dose alteplase during primary percutaneous coronary intervention according to ischemic time[J]. J Am Coll Cardiol, 2020, 75(12):1406‑1421. DOI: 10.1016/j.jacc.2020.01.041.
[45] 农京国, 田进文, 彭亮, 等. 冠状动脉内逆向精确溶栓术在急性ST段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗中应用的研究[J]. 中国循环杂志, 2016, 31(12):1160‑1164. DOI: 10.3969/j.issn.1000‑3614.2016.12.004.
[46] Pelliccia F, Greco C, Tanzilli G, et al. Long‑term outcome of patients with ST‑segment elevation myocardial infarction treated with low‑dose intracoronary thrombolysis during primary percutaneous coronary intervention: the 5‑year results of the DISSOLUTION Trial[J]. J Thromb Thrombolysis,2021,51(1):212‑216. DOI:10.1007/s11239‑020‑02157‑w.
[47] Zhu T, Zhang Q, Ding F, et al. Randomized comparison of intracoronary tirofiban versus urokinase as an adjunct to primary percutaneous coronary intervention in patients with acute ST‑elevation myocardial infarction: results of the ICTUS‑AMI trial[J]. Chinese Medical Journal,2013,126(16):3079‑3086. DOI:10.3760/cma.j.issn.0366‑6999.20130466.
[48] 张鹏飞, 张兴华. 校正的心肌梗死溶栓试验(TIMI)帧数‑‑冠状动脉介入领域中全新的定量指标[J]. 中国介入心脏病学杂志, 2004,12 (3):183‑184. DOI: 10.3969/j.issn.1004‑8812.2004.03.016.
[49] Gibson C M, Murphy S A, Rizzo M J, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group[J]. Circulation,1999,99(15):1945‑1950. DOI:10.1161/01.cir.99.15.1945.
[50] O′Gara P T, Kushner F G, Ascheim D D, et al. 2013 ACCF/AHA guideline for the management of ST‑elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2013,61(4):485‑510. DOI:10.1016/j.jacc.2012.11.018.
[51] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‑segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST‑segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2018, 39(2):119‑177. DOI: 10.1093/eurheartj/ehx393.
[52] 于一, 赵迎新, 史冬梅, 等. 准分子激光在经桡动脉复杂冠状动脉病变介入治疗中的应用[J]. 中国介入心脏病学杂志, 2016,24 (10):587‑591. DOI: 10.3969/j.issn.1004‑8812.2016.10.009.
[53] Carrick D, Oldroyd KG, McEntegart M, et al. A randomized trial of deferred stenting versus immediate stenting to prevent no‑or slow‑reflow in acute ST‑segment elevation myocardial infarction (DEFER‑STEMI)[J]. J Am Coll Cardiol, 2014, 63(20):2088‑2098. DOI: 10.1016/j.jacc.2014.02.530.
[54] Kelbæk H, Høfsten DE, Køber L, et al. Deferred versus conventional stent implantation in patients with ST‑segment elevation myocardial infarction (DANAMI 3‑DEFER): an open‑label, randomised controlled trial[J]. Lancet, 2016, 387(10034):2199‑2206. DOI: 10.1016/S0140‑6736(16)30072‑1.
[55] Bhat R A, Ali S M, Rathi A, et al. Outcome of Impella 2.5 use in patients undergoing Percutaneous Coronary Intervention in Henan, China: a case series[J]. Perfusion,2023,38(1):208‑213. DOI:10.1177/02676591211049018.
[56] Bhat R A, Maqbool S, Ali S M, et al. A study of management and biochemical outcomes in AMI patients supported with different mechanical devices in a single center[J]. J King Saud Univ Sci,2022,34(2):101777. DOI:10.1016/j.jksus. 2021.101777.
[57] Li X, Ge Z, Kan J, et al. Intravascular ultrasound‑guided versus angiography‑guided percutaneous coronary intervention in acute coronary syndromes (IVUS‑ACS): a two‑stage, multicentre, randomised trial[J]. Lancet,2024,403(10439):1855‑1865. DOI:10.1016/S0140‑6736(24)00282‑4.
[58] Jia H, Dai J, He L, et al. EROSION III: A multicenter RCT of OCT‑guided reperfusion in STEMI with early infarct artery patency[J]. JACC Cardiovasc Interv,2022,15(8):846‑856. DOI:10.1016/j.jcin.2022.01.298.
[59] Vos N S, Fagel N D, Amoroso G, et al. Paclitaxel‑coated balloon angioplasty versus drug‑eluting stent in acute myocardial infarction: The REVELATION randomized trial[J]. JACC Cardiovasc Interv,2019,12(17):1691‑1699. DOI:10.1016/j.jcin.2019.04.016.
[60] Zhang Y, Gao C, Liu H, et al. Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention[J]. Clin Exp Pharmacol Physiol,2013,40(4):289‑294. DOI:10.1111/1440‑1681.12065.
[61] 张优, 高传玉, 李牧蔚, 等. 早期应用替罗非班在急性ST段抬高型心肌梗死择期经皮冠状动脉介入治疗患者中的疗效[J]. 中华内科杂志, 2014, 53(4):273‑277. DOI:10.3760/cma.j.issn.0578‑1426.2014.04.006.
[62] 张优, 高传玉, 朱中玉, 等. 中高危非ST段抬高型急性冠状动脉综合征患者成功介入治疗后即刻应用替罗非班的疗效和安全性[J]. 中华心血管病杂志, 2013,41 (9):731‑735. DOI: 10.3760/cma.j.issn.0253‑3758.2013.09.002.
[63] 孔令才. 冠脉内注射依替巴肽与替罗非班对STEMI急诊介入治疗患者疗效及安全性的对比研究[D]. 扬州:扬州大学,2017.
[64] 纪军, 何胜虎, 徐日新, 等. 经抽栓导管注射依替巴肽或替罗非班对急性ST段抬高型心肌梗死患者急诊介入治疗疗效的对比研究[J]. 实用临床医药杂志, 2015, 19(23):7‑11. DOI: 10.7619/jcmp.201523003.
[65] Huang R I, Patel P, Walinsky P, et al. Efficacy of intracoronary nicardipine in the treatment of no‑reflow during percutaneous coronary intervention[J]. Catheter Cardiovasc Interv, 2006,68(5):671‑676. DOI:10.1002/ccd.20885.
[66] Mehta H H, Morris M, Fischman D L, et al. The spontaneous coronary slow‑flow phenomenon: reversal by intracoronary nicardipine[J]. J Invasive Cardiol,2019,31(3):42‑45. DOI: 10.25270/jic/18.00250.
[67] Khan K A, Qamar N, Saghir T, et al. Comparison of intracoronary epinephrine and adenosine for no‑reflow in normotensive patients with acute coronary syndrome (COAR Trial)[J]. Circ Cardiovasc Interv, 2022,15(2):e011408. DOI:10.1161/CIRCINTERVENTIONS.121.011408.
[68] Abu Arab T, Sedhom R, Gomaa Y, et al. Intracoronary adenosine compared with adrenaline and verapamil in the treatment of no‑reflow phenomenon following primary PCI in STEMI patients[J]. Int J Cardiol, 2024,410:132228. DOI: 10.1016/j.ijcard.2024.132228.
[69] Fu X H, Fan W Z, Gu X S, et al. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction[J]. Chin Med J (Engl), 2007,120(14):1226‑1231.
[70] 范卫泽, 傅向华, 姜云发, 等. 冠状动脉内应用山莨菪碱对急性心肌梗死介入治疗后无再流及心室功能和收缩同步性的影响[J]. 中华心血管病杂志, 2007, 35(10):908‑913. DOI: 10.3760/j.issn:0253‑3758.2007.10.009.
[71] Huang D, Qian J, Ge L, et al. REstoration of COronary flow in patients with no‑reflow after primary coronary interVEntion of acute myocaRdial infarction (RECOVER)[J]. Am Heart J,2012,164(3):394‑401. DOI:10.1016/j.ahj.2012.06.015.
[72] Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk[J]. Eur Heart J,2019,40(31):2632‑2653. DOI:10.1093/eurheartj/ehz372.
[73] Valgimigli M, Bueno H, Byrne R A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio‑Thoracic Surgery (EACTS)[J]. Eur Heart J,2018,39(3):213‑260. DOI:10.1093/eurheartj/ehx419.